TrialEuropean journal of nuclear medicine and molecular imaging2009

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

Marnix G E H Lam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.